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CLINICAL TRIALS AND OBSERVATIONS
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Patients with imatinib-resistant or
-intolerant accelerated-phase chronic my-
elogenous leukemia (CML-AP) have very
limited therapeutic options. Nilotinib is a
highly selective BCR-ABL tyrosine kinase
inhibitor. This phase 2 trial was designed to
characterize the efficacy and safety of nilo-
tinib (400 mg twice daily) in this patient popu-
lation with hematologic response (HR) as
primary efficacy endpoint. A total of 119 pa-
tients were enrolled and had a median dura-
tion of treatment of 202 days (range, 2-611
days). An HR was observed in 56 patients
(47%; 95% confidence interval [CI], 38%-
56%). Major cytogenetic response (MCyR)
was observed in 35 patients (29%; 95% CI,
21%-39%). The median duration of HR has
notbeenreached.Overallsurvival rateamong
the 119 patients after 12 months of follow-up
was 79% (95% CI, 70%-87%). Nonhemato-
logic adverse events were mostly mild to
moderate. Severe peripheral edema and
pleural effusions were not observed. The
most common grade 3 or higher hemato-
logic adverse events were thrombocytope-
nia (35%) and neutropenia (21%). Grade 3 or
higher bilirubin and lipase elevations oc-
curred in 9% and 18% of patients, respec-
tively, resulting in treatment discontinuation
in one patient. In conclusion, nilotinib is an
effective and well-tolerated treatment in
imatinib-resistant and -intolerant CML-AP.
This trial is registered at www.clinicaltrials.
gov as NCT00384228. (Blood. 2008;111:
1834-1839)
© 2008 by The American Society of Hematology
Introduction
Chronic myelogenous leukemia (CML) is a myeloproliferative
disorder resulting from a chromosomal rearrangement leading to
the formation of a novel fusion gene, BCR-ABL, which encodes the
BCR-ABL protein that has constitutive protein tyrosine kinase
activity. The oncogene results from a reciprocal translocation
between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11),
forming the Philadelphia chromosome (Ph), which can be detected
by cytogenetic analysis.1,2
In the absence of treatment, CML progresses within several
years from a chronic phase to an accelerated phase, and
eventually culminates in blastic phase and death.3 The treatment
of chronic-phase CML has been transformed by the introduction
of imatinib, an inhibitor of the BCR-ABL tyrosine kinase.
Newly diagnosed patients with chronic-phase CML treated with
imatinib (Gleevec/Glivec; Novartis, Basel, Switzerland) in the
International Randomized trial of Interferon- plus cytarabine
versus STI571 (IRIS) achieved complete cytogenetic response
(CCyR) rates in 87% of patients and had an estimated 5-year
survival of 89%. Only 6% of patients progress to an accelerated
phase or blastic phase during this time.4,5 In a large phase 2 trial,
20% of 454 patients in late chronic-phase CML who failed prior
interferon therapy, treated with imatinib, progressed to acceler-
ated phase or blastic phase within the first 3 years of therapy.6
Fewer than 15% of patients with CML are in accelerated phase
at the time of first diagnosis of CML.7 Therefore, most patients
diagnosed today with CML-AP are expected to have failed prior
imatinib therapy given either in the chronic or accelerated
phases of their leukemia. Before the introduction of imatinib,
the median survival of patients with accelerated phase CML was
less than 18 months.7 In a long-term follow-up of the large
imatinib phase 2 study in patients with accelerated phase, the
3-year survival rates of patients with and without a major
cytogenetic response (MCyR) were 85% and 52%, respectively.8
At the time the present study was initiated (May 2005), few
therapeutic options existed for the management of patients with
CML in accelerated phase who failed prior imatinib therapy.
These included bone marrow transplantation if a suitable donor
is available, or chemotherapy.
Submitted April 2, 2007; accepted November 18, 2007. Prepublished online as
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Resistance to imatinib has been associated with a heterogeneous
array of mechanisms that range from nonspecific multidrug resis-
tance to inherent genetic alterations in BCR-ABL. The most
frequently identified mechanism of acquired imatinib resistance is
point mutations in the BCR-ABL kinase domain. These mutations,
which are more frequently observed in patients with advanced
stages of the disease, are linked with impaired binding of imatinib
to BCR-ABL. In a cohort of 21 patients with accelerated phase and
imatinib resistance (described as primary and secondary resistance
in 5 and 16 patients, respectively), 52% had point mutations at the
time of resistance.9 In another retrospective analysis of 34 patients
with accelerated phase and imatinib failure, mutations were
identified in 17 patients (50%).10
Nilotinib (Tasigna [nilotinib], formerly known as AMN107;
Novartis) is a novel oral aminopyrimidine derivative that has been
rationally designed to be more selective against the Bcr-Abl
tyrosine kinase than imatinib.11-14 Like imatinib, it acts through
competitive inhibition of the ATP binding site of BCR-ABL. In vitro
nilotinib is 30 times more potent than imatinib against imatinib-
sensitive cell lines and 3 to 7 times more potent against imatinib-
resistant cell lines. In addition, nilotinib is effective in inhibiting
the growth of 32 of 33 cell lines bearing mutations causing imatinib
resistance, the exception being the T315I mutant.12-14 Results from
a phase 1 dose escalation study performed in imatinib-resistant
patients with CML and Ph acute lymphoblastic leukemia indi-
cated that nilotinib produced significant hematologic and cytoge-
netic responses in all phases of CML.15 Side effects potentially
related to nilotinib included grade 3 or 4 hematologic toxicities as
well as transient indirect hyperbilirubinemia and skin rash.
The current single-arm, open-label phase 2 study was under-
taken to evaluate the efficacy and safety of nilotinib in a larger
cohort of patients with imatinib-resistant and/or intolerant CML in
accelerated phase.
Methods
Study design and patient population
This study was conducted as a multicenter, international, single-arm,
open-label trial examining the efficacy and safety of nilotinib in patients
with hematologic malignancies. Patients at least 18 years of age and with
imatinib-resistant or -intolerant CML in accelerated phase were eligible.
CML in accelerated phase was defined by one or more of the following
characteristics present within 4 weeks of the start of treatment, and in the
absence of previous transformation to blastic phase: 15% or more but less
than 30% of blasts in blood or bone marrow, 30% or more blasts plus
promyelocytes in peripheral blood or bone marrow (providing that less than
30% of blasts were present in the bone marrow), peripheral blood basophils
of 20% or more, and/or thrombocytopenia of less than 100  109/L
unrelated to the administration of therapy.16 Patients with a clonal evolution
without any of these hematologic criteria were not eligible.
Imatinib resistance was defined by one of the following criteria during
treatment with at least 600 mg per day of imatinib: (1) disease progression
from chronic phase to accelerated phase occurring during imatinib therapy;
(2) disease progression defined as at least a 50% increase in peripheral
white blood cell count, blast count, basophils, or platelets during imatinib
therapy for accelerated phase; or (3) lack of hematologic response (HR) in
the bone marrow following a minimum of 4 weeks of imatinib therapy for
accelerated phase. In addition, patients receiving less than 600 mg per day
of imatinib were eligible for participation if BCR-ABL mutations were
found present at any one of the following amino acids by sequencing: L248,
G250, Q252, Y253, E255, T315, F317, and H396.
Imatinib intolerance was defined as the discontinuation of imatinib
therapy due to any of the following: grade 3 or 4 adverse events that
persisted in spite of optimal supportive care measures, or grade 2 adverse
events related to imatinib therapy in spite of optimal supportive care
measures that persisted for at least 1 month or that recurred more than
3 times whether the dose was reduced or discontinued. In addition, the
protocol definition of imatinib intolerance required the lack of an MCyR
with imatinib.
Patients were also required to have a World Health Organization (WHO)
Performance Status score of 2 or lower and normal serum electrolytes as well as
hepatic, renal, and pancreatic function. Serum potassium and magnesium were
required to be within the normal range and calcium (adjusted for serum albumin)
and phosphate had to be either within the normal range or correctable to within
normal range with supplements. Serum hepatic transaminase levels were
required to be less than or equal to 2.5 times the upper limit of normal (ULN) in
the absence of suspected disease involvement or less than or equal to 5 times
ULN when related to disease. Serum creatinine, amylase, and lipase were all
required to be less than 1.5 times ULN.
Patients were excluded if they had evidence of abnormal cardiac
function or cardiac conduction, including individuals who had a myocardial
infarction within the previous 12 months, individuals with left ventricular
ejection fractions of 45% or less by echocardiogram or multiple-gated
acquisition scan (MUGA), and individuals with a history of congenital long
QT syndrome or a corrected QT interval (QTc) of more than 450 millisec-
onds on screening ECG using QTcF (QTc according to Frederica formula).
Treatment with chemotherapy other than hydroxyurea was not permitted
within 1 week of starting therapy with nilotinib.
Study treatment
All patients were initially treated with nilotinib 400 mg orally twice daily
(800 mg total daily dose). Patients were instructed to fast for at least 2 hours
prior to and 1 hour after taking nilotinib. Dose escalation to 600 mg twice
daily was permitted in the absence of toxicity and at the discretion of the
investigator, under the following circumstances: failure to achieve return to
chronic phase by 1 month, loss of an achieved hematologic or cytogenetic
response, or disease progression. Dose reductions to 400 mg daily and
subsequently 200 mg daily were permitted for the management of toxicity.
If a dose delay of more than 21 days (or more than 42 days for grades 3 and
4 hematologic toxicity) was required, the patient was discontinued from the
study. National Cancer Institute Common Terminology Criteria (NCI-CTC)
for Adverse Events Version 3.0 were used to grade all adverse events.
Patients who experienced toxicity were evaluated at least once a week
following emergence of the toxicity until either resolution or stabilization of
the toxicity, or study discontinuation. Patients who experienced QTc
intervals of more than 480 milliseconds, grade 3 or higher hepatic toxicity
(aspartate aminotransferase [AST; serum glutamic oxaloacetic transami-
nase], alanine aminotransferase [ALT; serum glutamic pyruvic transami-
nase], total bilirubin greater than or equal to 2 times ULN), serum creatinine
greater than or equal to 2.0 times ULN, and grade 4 neutropenia and/or
thrombocytopenia had the study drug withheld until resolution to grade 1 or
lower or baseline for hepatic toxicity.
Treatment with nilotinib was continued until the patient experienced
disease progression, developed unacceptable toxicity that precluded any
further treatment, withdrew consent, and/or if the patient was felt by the
investigator to be no longer benefiting.
Efficacy
The primary efficacy variable was the rate of HR confirmed at 2 consecutive
visits at least 4 weeks apart, defined as either complete HR (CHR), bone
marrow response (otherwise termed “no evidence of leukemia,” or MR/
NEL) or a return to chronic phase (RTC). A CHR required that all the
following criteria be met: marrow blasts of less than 5%, no blasts in
peripheral blood, neutrophil counts of 1.5  109/L or more, platelet counts
of 100  109/L or more, basophils of less than 5% and no extramedullary
disease. A response was categorized as MR/NEL if all the following criteria
were met: marrow blasts of less than 5%, no blasts in peripheral blood,
neutrophil counts of 1.0  109/L or more, platelet counts of 20  109/L or
more, and no extramedullary disease. An RTC required all the following
criteria: less than 15% blasts in marrow and peripheral blood, less than 30%
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blasts plus promyelocytes in marrow and peripheral blood, less than 20%
basophils, and no extramedullary disease (with the exception of liver or
spleen enlargement). Secondary efficacy variables included time to HR,
duration of HR, MCyR, time to and duration of MCyR, and overall survival.
Cytogenetic response was based on assessment of at least 20 metaphases.
Responses were categorized as follows: CCyR, Ph 0%; partial cytogenetic
response (PCyR), Ph 1% to 35%; minor, Ph 36% to 85%; and minimal, Ph
66% to 95%. A MCyR included CCyR plus PCyR. In case of failure of
cytogenetic evaluation (because of insufficient number of metaphases [less
than 20 metaphases] or failure of cell growth), assessment by fluorescent in
situ hybridization (FISH) was permitted. HR was assessed on the basis of
(1) complete blood count (CBC) collected weekly for the first 8 weeks and
every 2 weeks thereafter; and (2) bone marrow aspirate and/or biopsy
performed on days 28, 56, and 84, and every 84 days thereafter.
BCR-ABL mutation assessments
Peripheral blood samples were obtained prior to the first dose of nilotinib.
The total blood RNA was reverse transcribed and amplified by nested
polymerase chain reaction (PCR) using primers located in the BCR and ABL
region of the BCR-ABL gene. The amplicons that extend over the entire
BCR-ABL tyrosine kinase domain (ranging from amino acids 230 to 490;
GenBank accession no. M14752) and the surrounding regions were then
screened for mutations by denaturing high-performance liquid chromatog-
raphy (D-HPLC) and direct sequencing technology. This BCR-ABL muta-
tional analysis was performed by 5 individual academic laboratories
(“Acknowledgments”). All 5 laboratories reported reliable detection of
mutant clones present at a frequency of 20% or more.
Safety
Safety assessments included regular monitoring of hematology and blood
chemistry values, vital signs, and physical examinations, including weight
and WHO performance status, and repeat cardiac assessments, including
12-lead ECGs and cardiac enzymes (cardiac troponin, creatine phosphoki-
nase [CK], and the MB isoenzyme of CK [CK-MB]). Adverse events and
serious adverse events were collected continuously throughout the trial.
Statistical analysis
The sample size was estimated based on the Fleming single-stage design to
test the null hypothesis P is less than or equal to .10, where P is the HR rate.
If the true response rate is a P value of .25 or greater, 64 patients are needed
to reject the null hypothesis with a power of 90% and a one-sided level of
significance of 2.5%. Enrollment of additional patients was allowed given
the high level of efficacy observed in the previous study.15 As prespecified
in the protocol, efficacy endpoints were analyzed in all the patients who
were enrolled at least 6 months prior to the cut-off date of 23 January 2007
(n  119). These patients had therefore at least 6 months of follow-up
unless they discontinued early for any reason. All patients were included in
the analysis according to the intent-to-treat principle. HR was calculated
based on raw hematologic parameters entered in the database. Response
rates were calculated with 95% confidence intervals (CIs) using Clopper-
Pearson limits. Time-to-event variables were summarized and are presented
using the Kaplan-Meier method. For patients achieving an HR, time to
progression was defined as the time from study start to disease progression
or death. Safety analyses were performed on all enrolled 119 patients.
Study conduct
The trial was conducted in accordance with the applicable regulatory
requirements. The protocol was reviewed and approved by an appropriate
institutional review board or ethics committee at every participating center.
Written informed consent was obtained from all patients in accordance with
the Declaration of Helsinki prior to participation in this study.
Results
Patients and demographics
Atotal of 119 patients were enrolled into the study from 36 participating
centers in 10 countries. The characteristics of the patient population
(N  119) at baseline are shown in Table 1 and include patients
with at least 6 months of follow-up or who were prematurely
discontinued from study treatment by the time of data cut-off. The
median duration of time since first diagnosis of CML was nearly
6 years, and the median duration of prior imatinib therapy was
976 days (range, 2-2163 days). Most patients had also received
prior therapies other than imatinib, including hydroxyurea (92%)
and interferon- (58%). Imatinib-resistant patients constituted 81%
of the population, with 49% previously treated with at least 800 mg
of imatinib at some time during their course.
The median dose intensity of therapy with nilotinib in all 119 pa-
tients was 790 mg/day (range, 180-1149 mg/day). For the 90 patients
who did not have dose escalation, this value was 727 mg/day (range,
180-800 mg/day); for the 29 patients who did have dose escalation, it
was 919 mg/day (range, 684-1149 mg/day). The median duration of
treatment with nilotinib was 202 days (range, 2-611 days).
Efficacy
Among the 119 patients analyzed for efficacy (“Methods; Effi-
cacy”), an overall HR rate of 47% (95% CI, 38%-56%) was
observed, as noted in Table 2. The median time to first HR in the 56
individuals experiencing an HR was 1 month (range, 0.8-5.5
months). The median duration of response was not reached at the
time of this analysis. As shown in Figure 1, of those patients
achieving HR, an estimated 70% (95% CI, 57%-83%) remained in
response at 12 months. It should be noted, however, that 30% of
Table 1. Patient characteristics at baseline
Characteristic N  119
Median age, y (range) 57 (22-79)
Male sex, % 56
Median mo since first diagnosis of CML (range) 71 (2-298)
Median WBC,  109/L (range) 12.7 (0.4-277)
Patients with WBC  50  109/L, % 21
Median blasts in peripheral blood, % (range) 0.4 (0-33)
Patients with blasts  15%, % 13
Median basophils in peripheral blood, % (range) 4 (0-62)
Patients with basophils  20%, % 13
Median platelet count, 109/L (range) 203 (4-3044)
Patients with platelets  50  109/L, % 21
Median blasts in bone marrow at baseline, % (range) 10.5 (0-28)
Patients with bone marrow blasts  15%, % 35
Extramedullary involvement, % 27
Median duration of prior imatinib therapy, d (range) 976 (2-2163)
Prior dose of imatinib therapy before entering the study, %
 400 mg 17.6
 600 mg 33.6
 800 mg 48.8
Prior hematopoietic stem cell transplantation, % 7.6
Other chromosomal abnormalities, no. patients (%) 35 (29)




Patients with imatinib resistance, % 81
Patients with imatinib intolerance, % 19
WBC indicates white blood cell.
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patients were not assessable for response, since as per protocol no
second post-baseline efficacy assessment was available at the time
of data collection of this report.
An MCyR was achieved in 35 patients (29%; 95% CI,
21%-39%). CCyRs occurred in 19 patients (16%). One patient with
a CCyR and 4 patients with a PCyR at baseline were entered in to
the study. In addition, 35 patients (29%) entered with additional
chromosomal abnormalities at baseline. The median time to MCyR
for the 35 individuals experiencing MCyR was 2 months (range,
0.9 to 8.5 months). The median duration of response was
15.4 months (range, 0.6-17.9 months). The HR rates in patients
with and without additional chromosomal abnormalities (ACAs)
were similar. Of 35 patients with ACAs, 21 (60%) responded,
compared with 23 (55%) of 42 patients with no ACAs. Data on
ACAs were not available for 42 patients.
The estimated rate of overall survival in all 119 study patients at
12 months was 79% (95% CI, 70%-87%; Figure 2).
Baseline BCR-ABL mutational assessment data were available
in 51 patients at the time of analysis: 17 different BCR-ABL
mutations involving 14 amino acids were detected in 57% (29 of
51) of the patients, 10% (5 of 51) of whom showed more than one
mutation. After 6 months of therapy, HR was achieved in 48% and
MCyR in 21% of patients with baseline mutations, compared with
45% and 36% of patients without baseline mutations, respectively
(Table 3). HR and/or MCyR were observed across a variety of
BCR-ABL mutant genotypes. Based on the preclinical data, the
T315I mutation is the only imatinib-resistant mutation among other
32 tested that showed in vitro insensitivity against nilotinib. A total
of 2 patients had the T315I mutation at baseline. One T315I
patient was not assessed for both hematologic and cytogenetic
responses at the time of analysis. The other patient achieved a
return to chronic phase and minimal cytogenetic response at day 29
after the first dosing and maintained the same response status until
he showed continued return to chronic phase but no cytogenetic
response after 141 days of nilotinib therapy. The fraction of T315I
mutant clone found in this patient, estimated at 50%, was copresent
with G250E at baseline. Postbaseline mutational assessment was
not available for this patient at the time of analysis, and the
frequency of the T315I clone was unknown at day 141. The
response seen in this patient may reflect the sensitivity of the
G250E clone and other BCR/ABL unmutated clones to nilotinib.
Safety
Nilotinib was well tolerated as indicated by the administration of a
median dose intensity that was 99% of that initially prescribed by
the protocol. Adverse events with a suspected relationship to
nilotinib are summarized in Table 4. The most commonly reported
nonhematologic events considered possibly related to nilotinib, and
of any grade severity, were rash (22%), pruritis (20%), constipation
(11%), headache, fatigue, nausea (10% each), diarrhea, and muscle
spasm (9%). Gastrointestinal and central nervous system (CNS)
hemorrhage of grade 3 or 4 severity were reported in less than 1%
and 2% of patients, respectively. The most commonly reported
hematologic adverse events of grade 3 or higher severity were
thrombocytopenia (35%) and neutropenia (21%; Table 5). Neutro-
penia and thrombocytopenia were generally manageable with dose
interruptions and/or reductions, which occurred in 16% and 24% of
patients, respectively. A total of 28% of patients required support
with hematopoietic growth factors or platelet transfusions. The
majority of serum biochemistry abnormalities observed with
nilotinib were mild to moderate in severity, resolved spontaneously
with continued dosing of nilotinib, and rarely led to discontinuation
of nilotinib. Grade 3 or 4 elevations in AST and ALT occurred in
1% and 2% of patients, respectively, and were manageable with
dose interruption and/or reduction. Grade 3 or 4 elevations of total
bilirubin occurred in 9% of patients. No patients discontinued
therapy because of an elevated transaminase or bilirubin. Grade 3
or 4 lipase elevations occurred in 18% of patients, mostly with
single isolated elevated values. Grade 3 or 4 elevations of serum
amylase occurred in 2% of patients. One patient discontinued from
therapy as a result of pancreatitis.
Table 2. Hematologic and cytogenetic response to nilotinib in
accelerated-phase CML
Parameter N  119 patients, no. (%)*
HR




No response (includes stable disease) 11 (9)
Progression 13 (11)
Death 3 (3)
Not assessable 36 (30)†
Cytogenetic response
MCyR (CCyRPCyR) 35 (29)
CCyR 19 (16)
PCyR 16 (13)
Minor cytogenetic response 16 (13)
Minimal cytogenetic response 28 (24)
No response/not assessable 19 (16)
*Patients with at least 6 months of follow-up unless discontinued the study early
(Methods).
†33% of patients had less than 2 postbaseline efficacy assessments for HR (in
absence of progressive disease or death).
Figure 1. Kaplan-Meier plot of time to progression for the 56 patients with
accelerated-phase CML who had an HR with nilotinib (40 censored observa-
tions).
Figure 2. Kaplan-Meier plot of overall survival for the 119 patients with
accelerated-phase CML (96 censored observations).
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There were 10 deaths, either occurring on study or within
28 days following discontinuation of nilotinib. Of these 10,
5 patients died of progressive CML, 1 of sepsis, 1 due to
intracranial hemorrhage, 1 due to pulmonary infection, 1 due to
metastatic melanoma (patient entered 6 months after melanoma
was removed by wide surgical excision considered curative and
expired due to metastasis, not considered related to nilotinib). One
patient died as a result of cardiac failure. The patient had a past
medical history at baseline of chronic obstructive pulmonary
disease (COPD). The patient had normal left ventricular function at
baseline. On study day 117, the patient was admitted to hospital
because of pneumonia and pulmonary edema. The patient was in
cardiac failure and died 5 days later. A preclinical signal indicating
that nilotinib could potentially prolong the QT interval resulted in
frequent electrocardiograms being performed during this study and
analyzed centrally. No patient experienced a prolongation in the
QTcF interval to greater than 500 milliseconds. Increases in the
QTcF interval from baseline of more than 60 milliseconds were
observed in 5 patients (4%). No episodes of torsades de pointes
were observed.
Discussion
Imatinib, the first Bcr-Abl tyrosine kinase inhibitor introduced in
clinical practice, has been shown to be remarkably efficacious in
patients with CML in accelerated phase.6,8 However, in a large
phase 2 study, the estimated rate of patients with disease progres-
sion after 1 year of therapy was 41%.6 Therefore, resistance
develops in a number of patients, and therapeutic options for
patients who are resistant to or intolerant of imatinib have
previously been limited.17 These have included chemotherapy or
hematopoietic allogeneic stem cell transplantation.
In comparison with imatinib, nilotinib was developed as a more
potent and more selective inhibitor of the Bcr-Abl protein tyrosine
kinase. Nilotinib inhibits the cellular autophosphorylation of
BCR-ABL (p210 BCR-ABL–transfected 32D cells) with a lower
mean IC50 value of 20 plus or minus 1 nM compared with 194 plus
or minus 7 nM with imatinib. In contrast, the mean IC50 for the
inhibition of the phosphorylation of PDGFR/ (A31 cells) was
similar for the 2 drugs (71 	 7 nM and 74 	 11 nM), and for the
inhibition of c-KIT (GIST882 cells) was higher with nilotinib
(200 	 13 nM) than with imatinib (96 	 12 nM).13 These data
indicate a higher selectivity of nilotinib against BCR-ABL. One of
the most important characteristics of nilotinib is its potency against
the majority of known BCR-ABL mutations associated with
imatinib resistance, with one exception being the T315I mutation.13
The results of this study demonstrate the high level of activity of
nilotinib in patients with CML-AP treatment failure with imatinib.
Nilotinib therapy resulted in a rate of confirmed HRs of 47%,
which were durable, with an estimated 70% rate of patients in
continuing response at 12 months. Importantly, 29% of patients
also achieved MCyR, which was complete in 16% of patients. The
estimated rate of overall survival at 12 months was 79%. In the
subset of patients with mutational assessment available, both
patients with or without a BCR-ABL mutation at baseline re-
sponded to therapy.
The most frequent adverse events were skin rash, pruritus, and
constipation. However, grade 3 or 4 events were uncommon. Interest-
ingly, consistent with an increased selectivity toward inhibition of
BCR-ABL versus PDGFR, severe edema or fluid retention syndromes
or pleural effusions (thought to be related to inhibition of PDGFR) were
not observed in this trial. Specifically, there was only one patient who
developed grade 3 or 4 pulmonary edema. This patient also had
pre-existing COPD and died of cardiac failure (the case is discussed in
the previous section). Importantly, grade 3 or 4 peripheral edema,
pericardial effusion, or pleural effusion were not reported in any
Table 3. Mutation analysis and response to nilotinib according to baseline mutation data in 51 patients with accelerated-phase CML
Mutation, n  51 No. patients (%) HR (CHRMR/NELRTC), no. (%) MCyR (CCyRPCyR), no. (%)
No mutation 22 (43) 10 (45) 8 (36)
Any mutation 29 (57) 14 (48) 6 (21)
M244V 5 (17) 3 (60) 1 (20)
G250E 3 (10) 1 (33) 1 (33)
Y253H 4 (14) 1 (25) 0 (0)
T315I 2 (7) 1 (50) 0 (0)
F317L 3 (10) 2 (67) 2 (67)
M351T 5 (17) 4 (80) 1 (20)
E459K 3 (10) 2 (67) 0 (0)
All others 10 (34) 5 (50) 2 (20)
Of the mutations listed, only G250E and Y253H lie within the P-loop. Mutations at baseline include mutations assessed on or before day 1 prior to study drug administration.
Response data are assessed within 6 months of treatment. All mutations observed only once in this group are captured in the category “All others.”
Table 4. Nonhematologic adverse events suspected to be related to
nilotinib












Abdominal pain 7 1
Anorexia 6 0
Arthralgia 5 0
Peripheral edema 5 0
Upper abdominal pain 5 0
Pain in extremity 5 0
*All grades are reported where the frequency was greater than 5%.
Table 5. Hematologic adverse events of grade 3 or higher
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patients. Grade 3 or 4 neutropenia or thrombocytopenia reported as
adverse events occurred in occurred in 21% and 35% of patients,
respectively. Cytopenia was manageable with dose interruption or
reduction. It must be noted, however, that patients in this trial were in
late-phase CML, had a median time from initial diagnosis of CML of
nearly 6 years and, consequently, were highly susceptible to developing
cytopenias.7 Laboratory abnormalities included grade 3 or 4 elevation of
serum lipase and bilirubin in 18% and 9% of patients, respectively.
These abnormalities are manageable since the majority resolved despite
continued therapy with or without dose reduction, and only one patient
discontinued treatment as a result of pancreatitis. The mechanism
underlying these observations is unknown.
Recently, the results of clinical trials with dasatinib, an inhibitor of
BCR-ABL, KIT, and PDGFR, as well as the Ephrin receptor and
SRC-family kinases, have been reported.18,19 In a phase 2 study in
patients with imatinib-intolerant or -resistant CML in accelerated phase,
the level of efficacy reported with dasatinib was similar to the present
study with nilotinib, with a rate of MCyR of 33%.19 However, the safety
profile of dasatinib was different. The main safety findings included
pleural effusion in 23% of patients (3% of grade 3 or 4), grade 3 or 4
gastrointestinal hemorrhage in 12% of patients, and grade 3 or 4
neutropenia and thrombopenia in 76% and 82% of patients, respec-
tively. The reasons for these differences are not clear and may be related
to the inhibition of tyrosine kinases other than BCR-ABL.
In summary, nilotinib produced significant hematologic and
cytogenetic responses in imatinib-resistant and -intolerant patients
with CML in accelerated phase. Similar rates of HRs were
observed in patients with and without BCR-ABL tyrosine kinase
mutations. Nilotinib was generally well tolerated. Nilotinib thus
provides an important alternative for the treatment of imatinib-
resistant and -intolerant patients with CML in accelerated phase.
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